Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic
  • Search Hotels in San Rafael

  • ROOMS:

Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)

Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
Biotech Stocks in Focus
Biotech Stocks Take Centerstage Amid Market Uncertainty: Actinium Pharmaceuticals (NYSE AMERICAN: ATNM), AstraZeneca (NASDAQ: AZN), Bristol Meyers (NYSE: BMY), Eli Lilly and Company (NYSE: LLY), Vincerx Pharma, Inc. (NASDAQ: VINC), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), Viking Therapeutics, Inc. (NASDAQ: VKTX), Phathom Pharmaceuticals (NASDAQ: PHAT), Rhythm Pharmaceuticals (NASDAQ: RYTM)

In the current economic backdrop where the Federal Reserve maintains a cautious stance on interest rate adjustments amid ongoing inflation concerns, the biotech sector emerges as an especially promising field for investors. The anticipation surrounding rate cuts, now deferred to possibly September as per the latest consumer price data, sets a unique stage for biotech stocks, which historically perform well in the months leading to such financial shifts.

The Biotech Sector’s Rising Star: Actinium Pharmaceuticals (ATNM)

A notable standout in the biotech landscape is Actinium Pharmaceuticals (NYSE AMERICAN: ATNM), which recently saw its price target raised by Maxim from $20 to $30. The adjustment follows the company's strategic move in acquiring another Ac-225 player, Fusion Pharma (FUSN), in collaboration with AstraZeneca (NASDAQ: AZN). This acquisition is part of a broader wave of consolidation in the radiopharmaceutical space, particularly concerning alpha emitters, a niche but rapidly advancing segment of cancer treatment technologies.

Maxim's endorsement of ATNM hinges on its positioning within a sparse field of alpha-emitting radiopharmaceuticals, a sector that has seen significant M&A activity. For instance, Bristol Meyers (NYSE: BMY) acquired RayzeBio for $4.1 billion to tap into its Ac-225 pipeline in December, while Lilly (NYSE: LLY) took over POINT Biopharma for $1.4 billion, targeting its portfolio of Lu-177 and Ac-225 based therapies in October 2023. These acquisitions underscore the high "scarcity value" of companies like Actinium, making ATNM a compelling investment candidate amidst the current M&A trend.

Recently, Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) announced that results from the Phase 3 SIERRA trial of Iomab-B in patients with a TP53 mutation have been accepted for oral presentation at the 50th Annual meeting of the European Bone Marrow Transplant Society (EBMT) being held April 14 – 17, 2024, in Glasgow, Scotland. Iomab-B is a targeted radiotherapy conditioning agent comprised of an anti-CD45 monoclonal antibody and Iodine-131 radioisotope payload. The Phase 3 SIERRA trial enrolled 153 patients with active relapsed or refractory acute myeloid leukemia (r/r AML) and compared outcomes of patients receiving Iomab-B and a bone marrow transplant (BMT) to those of patients receiving physician's choice of care in the control arm. In total, 24% of patients (37/153) in the SIERRA trial had a TP53 mutation, which is associated with poor outcomes, and 27 of the TP53 positive patients received Iomab-B. Iomab-B met the primary endpoint of durable Complete Remission (dCR) in the SIERRA trial with high-statistical significance (p<0.0001) and 100% of patients receiving a therapeutic dose of Iomab-B achieved BMT access and engagement. Click HERE to read more on ATNM. 

ATNM appears to be trading at discount prices considering overall market sentiment. Economists and Strategists now see the Fed waiting until at least September to cut interest rates and are increasingly entertaining the possibility of no reductions at all this year. Bank of America economists said there is a “real risk” that the Fed won’t cut until March 2025 “at the earliest,” though for now they’re still going with a December forecast. Hope remains that the inflation data turns lower in the next few months and gives the Fed room to ease. Other biotechnology stocks that been quietly ticking along in the background include Vincerx Pharma, Inc. (NASDAQ: VINC), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), and Viking Therapeutics, Inc. (NASDAQ: VKTX).

Broader Biotech Sector Trends

The broader biotech sector continues to benefit from favorable financing conditions and a vibrant outlook for mergers and acquisitions, coupled with innovative advancements in drug development. The Nasdaq Biotechnology Index's 14% rise since October illustrates this upward trajectory, buoyed by investor optimism and strategic industry movements.

Morgan Stanley predicts sustained outperformance for biotech stocks, particularly if interest rates trend downward, coupled with robust M&A activity and ongoing innovation. This environment is ripe for strategic investments, especially in companies engaged in late-stage therapies that are now also branching into earlier-stage treatments, reflecting a higher risk appetite among investors.

M&A Drives Sector Dynamics

The pace of biotech M&As remains vigorous, significantly exceeding historical averages. This trend not only enhances the sector's vitality but also increases the potential for high-value exits and partnerships. Companies specializing in Oncology, Immunology, and Rare Diseases are particularly in focus, with significant deals expected in the mid-stage development spectrum.

For instance, Phathom Pharmaceuticals (NASDAQ: PHAT) has seen its value appreciate following FDA approval for its new drug, Voquenza. Similarly, Vaxcyte and Rhythm Pharmaceuticals (NASDAQ: RYTM) continue to push the envelope in vaccine development and rare disease treatments, respectively, signaling ongoing opportunities for growth and investment.

For investors and traders, the biotech sector not only offers a landscape rich with potential for substantial returns but also a front-row seat to some of the most groundbreaking developments in medical technology. With the strategic positioning of companies like Actinium Pharmaceuticals and a keen eye on the evolving market dynamics, particularly in specialized segments like alpha-emitting radiopharmaceuticals, stakeholders can maximize their investments in this burgeoning field. The combination of a delayed interest rate cut, active M&A landscape, and continuous innovation creates a potent mix for those looking to invest in biotech during these exciting times.


Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or an endorsement of ATNM or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at has been compensated one thousand and six hundred dollars by a 3rd party Bullzeyemedia LLC for content distribution services on ATNM from April 17th to 19th, 2024. We own zero shares of ATNM. has been previously compensated three thousand and five hundred dollars by a 3rd party Bullzeyemedia LLC for content distribution services on ATNM for March 20th to March 28th, 2024. We own zero shares of ATNM. is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at It is always important to conduct thorough due diligence and exercise caution in is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. is not a fiduciary by virtue of any person’s use of or access to this content.


Media Contact
Company Name: Investor Brand Media
Contact Person: Ash K
Phone: (954) 593-5597
Country: United States

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.